CPA
BIIB icon

Capital Performance Advisors’s Biogen BIIB Stock Holding History

Capital Performance Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,561
Closed -$286K – 330
2026
Q1 		$286K Buy
1,561
+14
+0.9% +$2.58K 0.02% 340
2025
Q4 		$272K Buy
1,547
+2
+0.1% +$327 0.02% 333
2025
Q3 		$216K Sell
1,545
-234
-13% -$31.6K 0.04% 299
2025
Q2 		$223K Buy
1,779
+284
+19% +$35.4K 0.04% 226
2025
Q1 		$205K Buy
+1,495
New +$214K 0.04% 241
2024
Q4 		– Sell
-20
Closed -$3.88K – 482
2024
Q3 		$3.88K Buy
+20
New +$4.18K ﹤0.01% 1225

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Performance Advisors's BIIB Position: Q2 2026 in Review

Capital Performance Advisors sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,561 shares — an estimated $286K sold.

Capital Performance Advisors first reported a position in BIIB in Q3 2024 and held it in 6 quarters. The position peaked at $286K in Q1 2026. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Capital Performance Advisors reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 1,561 Biogen shares in Q2 2026, an estimated $286K.
  • Capital Performance Advisors first reported a position in Biogen in Q3 2024 and held it in 6 quarters.
  • Capital Performance Advisors's Biogen position peaked at $286K in Q1 2026.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.